Ibutilide was superior to DL-sotalol for terminating atrial flutter (70% and 56% vs 19%) and atrial fibrillation (44% vs 11% for the 2 mg dose; p<0.01).
RCT (n=308)
Double blind
randomised
Yes
Does ibutilide improve the successful conversion of atrial fibrillation or flutter compared to DL-sotalol in haemodynamically stable patients?
Ibutilide is highly effective and superior to DL-sotalol for rapidly terminating persistent atrial fibrillation or atrial flutter.
p-value: p=<0.01
OBJECTIVE: To compare the efficacy and safety of a single dose of ibutilide, a new class III antiarrhythmic drug, with that of DL-sotalol in terminating chronic atrial fibrillation or flutter in haemodynamically stable patients. DESIGN: Double blind, randomised study. SETTING: 43 European hospitals. PATIENTS: 308 patients (mean age 60 years, 70% men, 48% with heart disease) with sustained atrial fibrillation (n = 251) or atrial flutter (n = 57) (duration three hours to 45 days) were randomised to three groups to receive a 10 minute infusion of 1 mg ibutilide (n = 99), 2 mg ibutilide (n = 106), or 1.5 mg/kg DL-sotalol (n = 103). Infusion was discontinued at termination of the arrhythmia. MAIN OUTCOME MEASURE: Successful conversion of atrial fibrillation or flutter, defined as termination of arrhythmia within one hour of treatment. RESULTS: Both drugs were more effective against atrial flutter than against atrial fibrillation. Ibutilide was superior to DL-sotalol for treating atrial flutter (70% and 56% v 19%), while the high dose of ibutilide was more effective for treating atrial fibrillation than DL-sotalol (44% v 11%) and the lower dose of ibutilide (44% v 20%, p < 0.01). The mean (SD) time to arrhythmia termination was 13 (7) minutes with 2 mg ibutilide, 19 (15) minutes with 1 mg ibutilide, and 25 (17) minutes with DL-sotalol. In all patients, the duration of arrhythmia before treatment was a predictor of arrhythmia termination, although this was less obvious in the group that received 2 mg ibutilide. This dose converted almost 48% of atrial fibrillation that was present for more than 30 days. Concomitant use of digitalis or nifedipine and prolongation of the QTc interval were not predictive of arrhythmia termination. Bradycardia (6.5%) and hypotension (3.7%) were more common side effects with DL-sotalol. Of 211 patients given ibutilide, two (0.9%) who received the higher dose developed polymorphic ventricular tachycardia, one of whom required direct current cardioversion. CONCLUSION: Ibutilide (given in 1 or 2 mg doses over 10 minutes) is highly effective for rapidly terminating persistent atrial fibrillation or atrial flutter. This new class III drug, under monitored conditions, is a potential alternative to currently available cardioversion options.
Vos et al. (Mon,) conducted a rct in sustained atrial fibrillation or atrial flutter (n=308). Ibutilide vs. DL-sotalol 1.5 mg/kg was evaluated on Successful conversion of atrial fibrillation or flutter, defined as termination of arrhythmia within one hour of treatment (p=<0.01). Ibutilide was superior to DL-sotalol for terminating atrial flutter (70% and 56% vs 19%) and atrial fibrillation (44% vs 11% for the 2 mg dose; p<0.01).